Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle (NCT07028710) | Clinical Trial Compass
RecruitingNot Applicable
Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle
France40 participantsStarted 2026-01-12
Plain-language summary
This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.
Who can participate
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* At least 1 follicle of 14 mm or more
* Endometrium of 6 mm or more
* Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng/mL
* For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care).
Exclusion Criteria:
* Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period.
* Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion.
* Patient who has not given written consent to participate in the study.
* Patient not fluent in French.
* Patient under guardianship, curators or without social security coverage.
* Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Serum Progesterone Level on Day 3 After hCG Trigger
Timeframe: 3 Days After hCG Injection
Trial details
NCT IDNCT07028710
SponsorUniversity Hospital, Montpellier
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2028-06-15
Contact for this trial
Noémie RANISAVLJEVIC, Senior Lecturer - Hospital Pra